Loading clinical trials...
Loading clinical trials...
The primary objective is to evaluate if use of the AngioGuard™ XP improves myocardial reperfusion after PTCA as assessed by ST segment resolution at the end of PTCA.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Cordis US Corp.
NCT07660419 · Coronary Artery Disease (CAD), Coronary Stenosis
NCT06779630 · Coronary Artery Disease
NCT07565805 · Coronary Artery Disease (CAD)
NCT07560436 · Heart Failure With Preserved Ejection Fraction (HFPEF), Coronary Artery Disease
NCT07324720 · Coronary Artery Disease
Institut Cardiovasculaire Paris Sud
Massy
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions